Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 50 | 2026 | 367 | 9.940 |
Why?
|
| Early Detection of Cancer | 21 | 2026 | 449 | 4.290 |
Why?
|
| Mass Screening | 21 | 2026 | 541 | 3.780 |
Why?
|
| Zambia | 35 | 2026 | 50 | 3.310 |
Why?
|
| Breast Neoplasms | 26 | 2026 | 1723 | 3.190 |
Why?
|
| Uterine Cervical Dysplasia | 11 | 2026 | 43 | 2.750 |
Why?
|
| Papillomavirus Infections | 12 | 2026 | 376 | 2.000 |
Why?
|
| HIV Infections | 19 | 2026 | 2586 | 1.630 |
Why?
|
| Female | 87 | 2026 | 24698 | 1.530 |
Why?
|
| Humans | 93 | 2026 | 43102 | 1.200 |
Why?
|
| Developing Countries | 9 | 2023 | 113 | 1.140 |
Why?
|
| Cryotherapy | 7 | 2025 | 11 | 1.120 |
Why?
|
| Adult | 43 | 2026 | 13872 | 1.110 |
Why?
|
| Middle Aged | 40 | 2026 | 12222 | 1.110 |
Why?
|
| Community Health Planning | 4 | 2018 | 38 | 1.050 |
Why?
|
| Artificial Intelligence | 2 | 2026 | 112 | 1.030 |
Why?
|
| Medical Oncology | 3 | 2024 | 50 | 0.980 |
Why?
|
| Prospective Studies | 16 | 2026 | 1600 | 0.910 |
Why?
|
| Neoplasms | 8 | 2023 | 1377 | 0.870 |
Why?
|
| Africa South of the Sahara | 17 | 2026 | 52 | 0.840 |
Why?
|
| Ultrasonography, Mammary | 2 | 2020 | 8 | 0.840 |
Why?
|
| Gynecology | 1 | 2024 | 35 | 0.820 |
Why?
|
| Primary Health Care | 2 | 2024 | 380 | 0.780 |
Why?
|
| Endometrial Neoplasms | 1 | 2024 | 79 | 0.770 |
Why?
|
| Health Services Accessibility | 9 | 2024 | 706 | 0.710 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 58 | 0.660 |
Why?
|
| Papillomaviridae | 7 | 2024 | 142 | 0.640 |
Why?
|
| Health Promotion | 4 | 2019 | 704 | 0.620 |
Why?
|
| Algorithms | 2 | 2024 | 509 | 0.610 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 35 | 0.600 |
Why?
|
| Sensitivity and Specificity | 6 | 2026 | 611 | 0.590 |
Why?
|
| Program Evaluation | 3 | 2015 | 359 | 0.570 |
Why?
|
| Breast Diseases | 1 | 2018 | 5 | 0.570 |
Why?
|
| Delivery of Health Care | 7 | 2022 | 310 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2018 | 989 | 0.550 |
Why?
|
| Program Development | 3 | 2015 | 240 | 0.550 |
Why?
|
| Rural Health Services | 1 | 2018 | 48 | 0.540 |
Why?
|
| Healthcare Disparities | 6 | 2024 | 590 | 0.540 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 374 | 0.540 |
Why?
|
| Vaginal Smears | 5 | 2011 | 63 | 0.520 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2026 | 40 | 0.510 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2013 | 226 | 0.480 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 51 | 0.480 |
Why?
|
| Acetic Acid | 4 | 2021 | 19 | 0.470 |
Why?
|
| Electrosurgery | 3 | 2024 | 3 | 0.450 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 6 | 0.420 |
Why?
|
| Incidence | 7 | 2024 | 1078 | 0.410 |
Why?
|
| Referral and Consultation | 4 | 2024 | 142 | 0.410 |
Why?
|
| Women's Health | 6 | 2016 | 160 | 0.410 |
Why?
|
| Genital Neoplasms, Female | 2 | 2025 | 17 | 0.400 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 44 | 0.400 |
Why?
|
| Socioeconomic Factors | 7 | 2024 | 1234 | 0.390 |
Why?
|
| Telemedicine | 2 | 2020 | 234 | 0.370 |
Why?
|
| United States | 9 | 2024 | 5205 | 0.370 |
Why?
|
| Preventive Health Services | 2 | 2012 | 66 | 0.360 |
Why?
|
| Poverty | 4 | 2022 | 400 | 0.360 |
Why?
|
| Health Resources | 1 | 2011 | 37 | 0.340 |
Why?
|
| Vagina | 2 | 2025 | 89 | 0.310 |
Why?
|
| Aged | 13 | 2026 | 8214 | 0.310 |
Why?
|
| Attitude to Health | 3 | 2012 | 338 | 0.310 |
Why?
|
| Health Care Coalitions | 2 | 2006 | 11 | 0.310 |
Why?
|
| Health Status Disparities | 2 | 2024 | 719 | 0.300 |
Why?
|
| Rural Population | 6 | 2024 | 373 | 0.300 |
Why?
|
| Peer Group | 1 | 2010 | 177 | 0.290 |
Why?
|
| Reproductive Health Services | 1 | 2008 | 15 | 0.280 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 235 | 0.280 |
Why?
|
| Cervix Uteri | 3 | 2015 | 48 | 0.280 |
Why?
|
| Treatment Outcome | 5 | 2025 | 1604 | 0.270 |
Why?
|
| Cohort Studies | 9 | 2023 | 1759 | 0.270 |
Why?
|
| Computer Simulation | 2 | 2021 | 408 | 0.270 |
Why?
|
| Young Adult | 10 | 2026 | 5080 | 0.270 |
Why?
|
| Social Justice | 1 | 2007 | 65 | 0.260 |
Why?
|
| Prognosis | 4 | 2024 | 861 | 0.260 |
Why?
|
| Healthy People Programs | 1 | 2006 | 25 | 0.240 |
Why?
|
| Ovarian Neoplasms | 3 | 2005 | 415 | 0.240 |
Why?
|
| Cooperative Behavior | 3 | 2019 | 269 | 0.240 |
Why?
|
| Community Health Services | 1 | 2007 | 206 | 0.240 |
Why?
|
| Diathermy | 1 | 2025 | 1 | 0.230 |
Why?
|
| Quality of Life | 3 | 2026 | 616 | 0.230 |
Why?
|
| Survival Analysis | 5 | 2024 | 368 | 0.230 |
Why?
|
| Colposcopy | 2 | 2015 | 14 | 0.230 |
Why?
|
| Dairy Products | 1 | 2005 | 34 | 0.230 |
Why?
|
| Reproduction | 1 | 2005 | 94 | 0.220 |
Why?
|
| Patient Care Team | 1 | 2025 | 60 | 0.220 |
Why?
|
| HIV Seropositivity | 2 | 2018 | 196 | 0.220 |
Why?
|
| Clinical Competence | 2 | 2021 | 156 | 0.220 |
Why?
|
| Ablation Techniques | 1 | 2024 | 1 | 0.220 |
Why?
|
| ROC Curve | 1 | 2024 | 159 | 0.210 |
Why?
|
| Demography | 2 | 2015 | 195 | 0.210 |
Why?
|
| History, 20th Century | 1 | 2024 | 121 | 0.200 |
Why?
|
| Life Expectancy | 1 | 2024 | 72 | 0.200 |
Why?
|
| Radiotherapy | 1 | 2002 | 21 | 0.190 |
Why?
|
| Blood Transfusion | 1 | 2002 | 31 | 0.190 |
Why?
|
| Photography | 2 | 2015 | 50 | 0.190 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 3 | 0.190 |
Why?
|
| Income | 4 | 2022 | 160 | 0.190 |
Why?
|
| Specimen Handling | 1 | 2003 | 63 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2002 | 25 | 0.190 |
Why?
|
| Interleukin-10 | 1 | 2002 | 87 | 0.190 |
Why?
|
| Adolescent | 10 | 2025 | 6081 | 0.180 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 44 | 0.180 |
Why?
|
| Shoulder | 1 | 2021 | 10 | 0.180 |
Why?
|
| Arm | 1 | 2021 | 28 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 440 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2002 | 132 | 0.170 |
Why?
|
| Child, Orphaned | 1 | 2021 | 3 | 0.170 |
Why?
|
| Democratic Republic of the Congo | 1 | 2020 | 6 | 0.170 |
Why?
|
| Uterine Neoplasms | 1 | 2002 | 53 | 0.170 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 13 | 0.170 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 20 | 0.170 |
Why?
|
| Prevalence | 5 | 2015 | 1612 | 0.170 |
Why?
|
| Africa | 4 | 2022 | 82 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2002 | 144 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 291 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 238 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2020 | 259 | 0.150 |
Why?
|
| Hyperthermia, Induced | 1 | 2019 | 28 | 0.150 |
Why?
|
| Breast | 1 | 2020 | 139 | 0.150 |
Why?
|
| Learning | 1 | 2021 | 161 | 0.150 |
Why?
|
| Male | 8 | 2024 | 23409 | 0.150 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2019 | 8 | 0.150 |
Why?
|
| Obesity | 1 | 2007 | 1151 | 0.150 |
Why?
|
| Diet | 1 | 2005 | 826 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 561 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2019 | 2544 | 0.140 |
Why?
|
| HIV Seronegativity | 1 | 2018 | 41 | 0.140 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 37 | 0.140 |
Why?
|
| Age Factors | 2 | 2025 | 1154 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2015 | 863 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2022 | 502 | 0.130 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 154 | 0.130 |
Why?
|
| Alabama | 3 | 2006 | 52 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 495 | 0.120 |
Why?
|
| Uterine Cervical Diseases | 1 | 2015 | 14 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2015 | 47 | 0.120 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 83 | 0.120 |
Why?
|
| Observer Variation | 1 | 2015 | 59 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2018 | 363 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 1092 | 0.120 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 3156 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2015 | 107 | 0.110 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 6 | 0.110 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 1067 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 27 | 0.110 |
Why?
|
| Mississippi | 2 | 2007 | 129 | 0.110 |
Why?
|
| Cytological Techniques | 1 | 2014 | 14 | 0.110 |
Why?
|
| Logistic Models | 2 | 2017 | 1009 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 3 | 2025 | 179 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 2 | 2015 | 174 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2025 | 518 | 0.110 |
Why?
|
| Topography, Medical | 1 | 2013 | 2 | 0.110 |
Why?
|
| South Africa | 3 | 2022 | 38 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 241 | 0.100 |
Why?
|
| Pregnancy | 3 | 2023 | 1772 | 0.100 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 31 | 0.100 |
Why?
|
| Sex Education | 1 | 2013 | 36 | 0.100 |
Why?
|
| HIV | 1 | 2013 | 100 | 0.100 |
Why?
|
| Probability | 1 | 2013 | 82 | 0.100 |
Why?
|
| Social Class | 2 | 2016 | 291 | 0.090 |
Why?
|
| Fertility | 2 | 2023 | 62 | 0.090 |
Why?
|
| Genital Diseases, Female | 1 | 2012 | 38 | 0.090 |
Why?
|
| Survival Rate | 2 | 2020 | 355 | 0.090 |
Why?
|
| Metagenome | 1 | 2012 | 31 | 0.090 |
Why?
|
| Child | 4 | 2022 | 3443 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.090 |
Why?
|
| Urban Population | 3 | 2024 | 374 | 0.090 |
Why?
|
| Patient Preference | 1 | 2012 | 60 | 0.090 |
Why?
|
| Killer Cells, Natural | 2 | 2002 | 104 | 0.090 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 14 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2006 | 116 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2002 | 411 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2011 | 25 | 0.090 |
Why?
|
| Patient Participation | 1 | 2012 | 94 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 497 | 0.080 |
Why?
|
| Education | 1 | 2010 | 60 | 0.080 |
Why?
|
| Nurses | 1 | 2010 | 55 | 0.080 |
Why?
|
| Minority Groups | 2 | 2007 | 690 | 0.080 |
Why?
|
| Focus Groups | 2 | 2012 | 423 | 0.080 |
Why?
|
| Data Collection | 1 | 2010 | 210 | 0.080 |
Why?
|
| Beneficence | 1 | 2007 | 2 | 0.070 |
Why?
|
| Biopsy | 1 | 2008 | 177 | 0.070 |
Why?
|
| Personal Autonomy | 1 | 2007 | 22 | 0.070 |
Why?
|
| Risk Factors | 3 | 2021 | 3994 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 934 | 0.060 |
Why?
|
| Community-Institutional Relations | 2 | 2006 | 219 | 0.060 |
Why?
|
| Culture | 1 | 2007 | 172 | 0.060 |
Why?
|
| Social Change | 1 | 2006 | 19 | 0.060 |
Why?
|
| State Government | 1 | 2006 | 21 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 201 | 0.060 |
Why?
|
| Social Environment | 1 | 2007 | 218 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2006 | 89 | 0.060 |
Why?
|
| Vaccination | 2 | 2021 | 355 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2005 | 24 | 0.060 |
Why?
|
| DNA, Ribosomal | 1 | 2025 | 39 | 0.060 |
Why?
|
| Maternal Mortality | 1 | 2005 | 26 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2025 | 22 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2006 | 120 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 102 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2005 | 93 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2025 | 203 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2025 | 206 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2018 | 452 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 140 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2007 | 469 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 220 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2025 | 515 | 0.050 |
Why?
|
| Sociology, Medical | 1 | 2003 | 7 | 0.050 |
Why?
|
| Public Health | 1 | 2007 | 424 | 0.050 |
Why?
|
| Perforin | 1 | 2002 | 11 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2002 | 6 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2002 | 57 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 32 | 0.050 |
Why?
|
| Reproductive History | 1 | 2023 | 27 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2002 | 53 | 0.050 |
Why?
|
| Parity | 1 | 2023 | 59 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2022 | 16 | 0.050 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.050 |
Why?
|
| Qualitative Research | 2 | 2018 | 574 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2023 | 161 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2002 | 48 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2002 | 22 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 1063 | 0.050 |
Why?
|
| Mammography | 2 | 2019 | 212 | 0.050 |
Why?
|
| Health Status | 1 | 2026 | 442 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 161 | 0.050 |
Why?
|
| Cause of Death | 1 | 2022 | 186 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2002 | 91 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2006 | 486 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 189 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 184 | 0.040 |
Why?
|
| Cancer Care Facilities | 1 | 2021 | 20 | 0.040 |
Why?
|
| Cell Division | 1 | 2002 | 311 | 0.040 |
Why?
|
| Exercise | 1 | 2007 | 692 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 224 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 175 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 508 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 279 | 0.040 |
Why?
|
| Research | 1 | 2022 | 181 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 306 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Family | 1 | 2021 | 195 | 0.040 |
Why?
|
| Smoking | 1 | 2006 | 1024 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 490 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2019 | 41 | 0.040 |
Why?
|
| Cytokines | 1 | 2002 | 678 | 0.040 |
Why?
|
| Time Factors | 1 | 2002 | 1857 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 108 | 0.030 |
Why?
|
| Population Groups | 1 | 2017 | 59 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 760 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 36 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1546 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 587 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 78 | 0.030 |
Why?
|
| Health Education | 2 | 2012 | 363 | 0.030 |
Why?
|
| Cameroon | 1 | 2015 | 35 | 0.030 |
Why?
|
| Colorimetry | 1 | 2016 | 53 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1081 | 0.030 |
Why?
|
| Marriage | 1 | 2013 | 21 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 883 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 232 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 1019 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 311 | 0.020 |
Why?
|
| Counseling | 1 | 2013 | 138 | 0.020 |
Why?
|
| Vaginosis, Bacterial | 1 | 2012 | 8 | 0.020 |
Why?
|
| Government Programs | 1 | 2012 | 29 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2011 | 16 | 0.020 |
Why?
|
| Probiotics | 1 | 2012 | 37 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 287 | 0.020 |
Why?
|
| Bacteria | 1 | 2012 | 293 | 0.020 |
Why?
|
| Social Support | 1 | 2012 | 445 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 513 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 4 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 17 | 0.020 |
Why?
|
| Cotinine | 1 | 2006 | 44 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 173 | 0.010 |
Why?
|
| Health Priorities | 1 | 2006 | 25 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 24 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 53 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 53 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2005 | 47 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 153 | 0.010 |
Why?
|
| Cisplatin | 1 | 2005 | 98 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 237 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 186 | 0.010 |
Why?
|